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Summary
AIMS OPF THE STUDY: Healthy adults have had the op-
tion to receive prescriptionless vaccination against influen-
za in pharmacies of several Swiss cantons since the 2015/
16 influenza season. We aimed to assess in a cost-benefit
analysis the resulting net benefits for the Swiss economy
and public health, and the benefits that could be expect-
ed if an extension of the current vaccination recommenda-
tions was implemented.
METHODS: The proportion of influenza vaccines adminis-
tered in pharmacies was calculated from data provided by
pharmacies entering information in phS-net.ch, data from
vaccines covered by insurance companies, and vaccine
supply data. The economic and public health impact was
estimated in a cost-benefit analysis based on published
data.
RESULTS: In the 2016/17 and 2017/18 influenza seasons,
7306 of a total of 1.07 million (0.7%) and 15,617 of a total
of 1.15 million (1.4%) influenza vaccine doses, respective-
ly, were administered in pharmacies in Switzerland. The
net cost savings for the economy due to vaccination in
pharmacies in the 2016/17 and 2017/18 seasons were
CHF 66,633 and CHF 143,021, respectively. In the 2017/
18 season, this resulted –in a net saving per 100,000 in-
habitants of CHF 1918, 94.4 cases of illness, 17.6 visits to
primary care physicians, 0.328 hospitalisations, 1.1 hos-
pitalisation days, 0.019 deaths prevented, and 0.353 life-
years gained. Influenza vaccination proved to be cost-
effective provided that a vaccine efficacy of 59% is
exceeded. Extrapolations for the healthy, working-age
population revealed that a vaccination coverage rate of
50% and a vaccine efficacy of 70% could save the Swiss
economy CHF 18.4 million annually.
CONCLUSIONS: The service allowing citizens to receive
influenza vaccination in Swiss pharmacies is sparsely
used. Since influenza vaccination is cost-beneficial as
soon as vaccine efficacy surpasses a critical threshold,
an extension of the vaccine recommendation for healthy,
working-age adults should be considered from an eco-
nomic point of view.
Keywords: influenza, vaccine, pharmacy, cost-benefit,
economic impact
Introduction
Influenza is a highly contagious disease, with transmission
rates of up to 25% observed in household studies [1]. It has
been estimated that between 10% and 20% of the popula-
tion are infected with influenza each year [2]. Children are
the main reservoir of the disease, but owing to its high in-
fectivity, adults are also frequently affected. However, in-
fection rates vary from year to year depending on the vir-
ulence of the circulating influenza strains, their antigenic
similarity to circulating viruses from previous years and
vaccination coverage. Each year between December and
April, an influenza epidemic with variable magnitude can
be observed in Switzerland [3].
Patients with influenza infections may be fully asymp-
tomatic, suffer from mild symptoms of a common cold,
or may present with severe disease requiring hospitalisa-
tion. It is estimated that between 100,000 and more than
300,000 visits to primary care physicians in Switzerland
occur every year as a result of influenza infections [4]. In-
fluenza can even be fatal, and most deaths from influenza
occur in elderly people aged 65 and over, who are prone
to developing severe disease because of comorbidities. In-
fluenza is one of the leading causes of death in developed
countries owing to its high infectivity, which results in a
high yearly incidence. In Switzerland, influenza is estimat-
ed to cause 1000 to 5000 hospitalisations and up to 1500
deaths each year [5].
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The annual economic loss induced by influenza is substan-
tial. The cost of excess hospitalisations in connection with
influenza epidemics in the USA was already estimated at
more than USD 1 billion at the beginning of the 1990s
[6]. For Switzerland, models have assumed that the annu-
al direct costs for the Swiss healthcare system amount to
around CHF 100 million. If all damages incurred by soci-
ety are taken into account, including costs resulting from
sick leave, the annual economic costs increase to almost
CHF 300 million [7].
Various measures can help prevent transmission and the
development of influenza. Of these, influenza vaccination
is considered the most effective preventive measure [8, 9].
Vaccination reduces the risk of influenza and influenza-
associated mortality, and is considered the most effective
way to reduce the severity of the disease and prevent com-
plications [10]. Unfortunately, as a result of antigen drift
and waning immunity over time, immunisation needs to
be repeated annually. The efficacy of influenza vaccination
after a single dose is significantly lower than that of other
vaccinations. It has been reported to be in the range of
30‒80%, depending on the population vaccinated and in-
fluenza season studied, with elderly people showing a re-
duced response to immunisation [11–14]. Various health
authorities, such as the German Robert Koch Institute or
the Swiss Federal Office of Public Health (FOPH), recom-
mend annual influenza vaccination for people at increased
risk [9, 15], whereas others, such as the United States of
America or the province of Ontario, Canada, pursue a uni-
versal vaccination approach for influenza. The Swiss vac-
cination recommendations, which also provide the basis
for cost absorption by health insurers, have so far main-
ly covered the main risk groups (elderly aged >65 years,
women during pregnancy or within 4 weeks after giving
birth, premature infants more than 6 months of age for the
first two influenza seasons, and those with chronic dis-
eases) and people with frequent contact with risk groups
(including healthcare workers) or infants less than 6 month
of age, whereas other population groups have had the op-
portunity to have themselves immunised by a physician at
their own expense [16]. As a result, vaccination rates in the
Swiss population vary according to age group [4]. Based
on sales of influenza vaccines in Switzerland and surveys,
the influenza vaccination rate in the Swiss population is es-
timated to be approximately 10%.
In some cantons, Swiss pharmacists who have completed
training in vaccine administration have been authorised
to offer vaccination against seasonal influenza without a
physician’s prescription to healthy adults at these cus-
tomers’ own expense since the 2015/2016 influenza sea-
son. In this first influenza season, vaccination was avail-
able in pharmacies in 5 out of 26 cantons, but the number
rose to 18 by the 2017/18 season. This service, offered by
pharmacies, supports the Swiss National Strategy on Vac-
cination, which aims to increase vaccination coverage rates
in general [17].
The impact of influenza vaccinations administered in phar-
macies in Switzerland on the economy and the popula-
tion’s health has not yet been assessed. Therefore, the pri-
mary aim of this study was to describe the extent of
influenza vaccination administered by pharmacies in the
influenza seasons 2016/17 and 2017/18 and to assess in a
cost-benefit analysis the resulting net benefits for the Swiss
economy and public health. Our secondary aim was to as-
sess the benefits that could be expected if an extension of
vaccination recommendations with regard to working-aged
adults was implemented.
Materials and methods
In order to be able to assess the impact of influenza vacci-
nations administered in pharmacies in relation to the entire
number of vaccinations in Switzerland, we collected data
on the various vaccine delivery channels by accessing dif-
ferent data sources. These data were then normalised using
population data.
Vaccine supply data
The data for influenza vaccine doses supplied to Switzer-
land by manufacturers are collected by the Swiss FOPH
on an annual basis and were made available for the years
1996 to 2017. In order to present the distribution of in-
fluenza vaccinations by age group and prescription status,
it was assumed that all vaccinations administered outside
pharmacies and physicians’ offices (e.g., through company
physicians in companies with vaccine campaigns) were ad-
ministered in the 19‒65 years age group. This assumes that
the risk groups of chronically ill minors and elderly citi-
zens neither have easy access to non-prescription vaccina-
tions (e.g., through company physicians) nor make use of
it. They are usually vaccinated by their family physicians,
and these costs are covered by insurance companies.
Vaccinations in pharmacies
Vaccination data from pharmacies were made available
free of charge by pharmaSuisse, the national umbrella or-
ganisation of pharmacists. PharmaSuisse collected the data
on influenza vaccinations carried out in pharmacies autho-
rized to vaccinate for the 2016/2017 and 2017/2018 in-
fluenza seasons.. These pharmacies administer influenza
vaccinations in the participating cantons without a physi-
cian’s prescription and record customer data in phS-net.ch.
The registration in phS-net.ch is voluntary, which is why
the absolute number of pharmacies carrying out vacci-
nations is underestimated [18]. Variables that were made
available by pharmaSuisse were canton of residence, year
of birth, date of vaccination and sex of the immunised per-
sons. In addition, data on the number of pharmacies autho-
rised to vaccinate per canton were provided.
Vaccinations covered by health insurance
Data on vaccinations covered by health insurance
providers were purchased from Sasis AG, a company of
the Santésuisse group, for the 2016/17 and 2017/18 in-
fluenza seasons. This datapool of Swiss health insurers in-
cludes data on all items covered by basic health insurance.
Basic health insurance reimburses the costs of influenza
vaccination for certain groups of people (those over 65
years of age and other risk groups), provided that the vacci-
nation is administered based on a physician’s prescription.
Over-the-counter vaccination in pharmacies is not covered
by basic health insurance. Of note, there are insurance
companies that also reimburse the related bills submitted
by patients with additional insurance plans who do not be-
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long to a risk group [19]. These bills are not recorded in the
Sasis datapool.
Supplementary table S1 in appendix 1 lists the vaccina-
tions that were queried, as of 17 July 17 2018. The lag be-
tween influenza season and data retrieval was considered
appropriate as approximately 95% of services offered by
healthcare providers are billed within 6 months of delivery.
Population data
The raw data on the population by canton (available for the
years 1991‒2016), on the age distribution of the popula-
tion and on employment situation were downloaded from
the website of the Swiss Federal Statistical Office (FSO)
or, for data not yet available at the time of the download
(resident population, 2017), provided directly by the FSO
[20–22].
Calculation of the economic loss due to influenza and
of the benefits of influenza vaccination
The methodology for calculating the economic and public
health loss due to influenza and the benefits of influenza
vaccination was based on a study entitled “The Economic
Impact of Influenza in Switzerland – Interpandemic Situa-
tion”, published in 2003 by James Piercy and Adrian Miles
[4], which was prepared on behalf of the Swiss FOPH
based on 1999 data. In this comprehensive study, the au-
thors carried out a cost-effectiveness analysis of influen-
za vaccination in Switzerland. The assumptions and results
obtained in the work of Piercy and Miles were adopted
as the basis for our calculations and transformed to the
current population of interest (healthy adults aged 19‒65
years).
Supplementary table S2 (appendix 1) shows an overview
of the assumptions and results on which the following
analyses are based. Based on the assumption that the pa-
rameters of teenagers between 15 and 18 years of age do
not differ significantly from the 19‒65 years age group, as-
sumptions from the 15‒65 years age group that were used
by Piercy and Miles were applied for the analysis of the
19‒65 years age group in the present paper. The cost fac-
tors listed in table 1 for the 2017/18 influenza season were
derived from the information given in table S2, enriched by
current data on the base rate, cost weights from diagnosis-
related groups, taxpoint values, duration of primary care
physician visits and influenza vaccination costs [23–25].
Net savings and marginal effectiveness of influenza
vaccination
Our main goal was to calculate the net economic impact of
influenza immunisation carried out in pharmacies. Net sav-
ings were calculated as the difference between the savings
made and the costs incurred by vaccination (including the
costs of adverse effects). In formal terms, the net savings
from influenza vaccination can be calculated as follows:
Net savings = savings from vaccination − vaccination costs
= influenza cases prevented × cost per case of illness −
number vaccinated × costs per vaccination = population
size × proportion with disease (attack rate) × proportion
vaccinated × effectiveness of vaccination × costs per ill-
ness case − population size × proportion vaccinated × cost
per vaccination.
This formula can then be resolved for the marginal effec-
tiveness of vaccination – that is, the effectiveness needed
to achieve zero net savings:
Marginal effectiveness = costs per vaccinecosts per illness case × attack rate
From this, it can be concluded that marginal effectiveness
is higher with increasing costs per vaccination and/or re-
ductions in costs per case of illness or attack rates. Net sav-
ings of at least CHF 0 are always achieved if vaccine effec-
tiveness is greater than marginal effectiveness, regardless
of the size of the vaccinated population. For the assump-
tions of Piercy and Miles, for example, a marginal effec-
tiveness of CHF 20.64 / (CHF 537.63 × 0.1) = 38% is nec-
essary – that is to say, a net benefit can be expected from a
vaccine efficacy of 38% or more.
Statistical analyses
Differences in categorical data were examined with Fish-
er's exact test, and differences in continuous variables with
the Wilcoxon rank-sum test or Student’s t-test. The data
were analysed using Stata® Version 13.1 (Stata Corpora-
tion, College Station, TX). Two-sided p-values <0.05 were
considered statistically significant.
Table 1: Parameters for estimating the economic benefits of influenza vaccination and the economic loss due to influenza in the 2017/18 influenza season.
Cost factors Piercy and Miles,
2003 [4]
Current study
Costs per vaccine; includes vaccine administration and adverse effects, CHF 20.65 38.35
Costs per case of influenza in healthy, working adults, CHF 537.60 655.40
Employment rate 0.78 0.84
Median household income, CHF 3456 4152
Median costs per working day lost, CHF 159 192
Costs per visit to a primary care physician, CHF 120 120
Hospitalisation costs Base rate for non-university-affiliated hospitals, CHF n.a. 9,547
Cost weight for pneumonia n.a. 0.631
Hospitalisation costs for pneumonia, CHF 7670 6024
Cost weight for other respiratory infections n.a. 0.631
Hospitalisation costs for other respiratory infections, CHF 8133 6024
Cost weight for heart failure n.a. 0.883
Hospitalisation costs for heart failure, CHF 8099 8430
n.a. = not applicable
For the current study, hospitalisation costs are calculated by multiplying cost weights for individual disease categories with the base rate.
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Results
Influenza vaccinations in Switzerland
In the 2016/17 influenza season, 1,071,000 vaccine doses
were delivered to Switzerland, covering 12.7% of the total
population under the assumption that all vaccines supplied
were administered (table 2). In comparison with the 2016/
17 influenza season, more vaccine doses were supplied
in the 2017/18 influenza season and the proportion of the
population who had their immunisation reimbursed by
their health insurance provider decreased (4.7% in 2016/
17 vs 4.5% in 2017/18, p <0.001), whereas the proportion
vaccinated in pharmacies increased (0.1% vs 0.2%, p
<0.001). Of note, more than half of all vaccine doses were
administered outside the healthcare system or pharmacies
in both influenza seasons. Unvaccinated individuals be-
tween 19 and 65 years of age represented more than 50%
of the total Swiss population in each influenza season.
Influenza vaccinations in pharmacies
In the 2017/18 season, the proportion of vaccinating phar-
macies in the individual, participating cantons varied be-
tween 9.7% (Geneva) and 57.4% (Basel-Landschaft ) of all
pharmacies per canton (table 3). Throughout Switzerland,
340 pharmacies authorised to vaccinate were registered in
the 2017/18 influenza season, accounting for 24.5% of all
pharmacies. Compared with the 2016/17 season, their rel-
ative proportion had increased by 4.3% (p = 0.007).
In the 2017/18 season, 83.4% of the Swiss population lived
in cantons with authorised pharmacies. In the 2016/17 and
2017/18 influenza seasons, 0.7% and 1.4%, respectively,
of all vaccine doses delivered in Switzerland were admin-
istered in these pharmacies. Around 30% of those vaccinat-
ed in pharmacies were over 65 years old, and this propor-
tion did not change between the two periods (table 4). The
proportion of vaccinated 19- to 65-year-olds was 0.09% of
the total population in the 2016/17 season and 0.2% in the
2017/18 season (p <0.001).
Table 2: Distribution of influenza vaccine in the Swiss population, 2016/17 and 2017/18 influenza seasons.
Influenza season
2016/17 2017/18
Population size 8,419,550 (100) 8,482,152 (100)
Distribution of vaccines Vaccine doses delivered 1,071,000 (12.7) 1,152,000 (13.6)
Vaccine doses reimbursed by health insurance providers 393,993 (4.7) 384,042 (4.5)
Vaccine doses administered in pharmacies 7306 (0.09) 15,617 (0.18)
Vaccine coverage accord-
ing to age group
0‒18 years Unvaccinated 1,589,979 (18.9) 1,598,928 (18.9)
Vaccinated (reimbursed by health insurance providers) 9107 (0.11) 8786 (0.10)
Vaccinated (administered in pharmacies) 100 (0.001) 164 (0.002)
19‒65 years Unvaccinated 4,621,279 (54.9) 4,559,567 (53.8)
Vaccinated (reimbursed by health insurance providers) 89,652 (1.1) 85,058 (1.0)
Vaccinated (administered in pharmacies) 4966 (0.06) 10,659 (0.13)
Vaccinated (outside pharmacy or health insurance) 669,701 (7.9) 752,341 (8.9)
>65 years Unvaccinated 1,137,292 (13.5) 1,171,657 (13.8)
Vaccinated (reimbursed by health insurance providers) 295,234 (3.5) 290,198 (3.4)
Vaccinated (administered in pharmacies) 2240 (0.03) 4794 (0.06)
Data are n (%).
Table 3: Pharmacies authorised to vaccinate in Switzerland in the 2016/17 and 2017/18 influenza seasons.
Canton Pharmacies 2016/17 Pharmacies authorised to
vaccinate 2016/17
Pharmacies 2017/18 Pharmacies authorised to
vaccinate 2017/18
p-value*
Bern 172 48 (27.9) 173 59 (34.1) 0.25
Basel-Landschaft 47 26 (55.3) 47 27 (57.4) 1.00
Fribourg 72 20 (27. 8) 72 15 (20.8) 0.44
Geneva 176 10 (5.7) 175 17 (9.7) 0.17
Graubünden 43 19 (44.2) 43 17 (39.5) 0.83
Jura 19 6 (31.6) 19 6 (31.6) 1.00
Lucerne 36 9 (25.0) n.a.
Neuchâtel 57 14 (24.6) 57 16 (28.1) 0.83
Nidwalden 3 1 (33.3) n.a.
Saint Gallen 54 11 (20.4) 53 12 (22.6) 0.82
Schaffhausen 13 2 (15. 4) 13 2 (15. 4) 1.00
Solothurn 28 9 (32.1) 27 13 (48.1) 0.28
Schwyz 16 2 (12.5) 17 6 (35.3) 0.22
Thurgau 24 4 (16.7) 24 6 (25.0) 0.72
Vaud 246 20 (8.1) 245 37 (15.1) 0.017
Valais 122 12 (9.8) 123 18 (14.6) 0.33
Zug 16 7 (43.8) n.a.
Zurich 240 65 (27.1) 242 72 (29.8) 0.55
Switzerland 1329 268 (20.2) 1385 340 (24.5) 0.007
n.a. = not applicable Data are n (%). Percentages refer to the total number of pharmacies per canton or in Switzerland. In the cantons of Aargau, Appenzell Innerrhoden, Appenzell
Ausserrhoden, Basel-Stadt, Glarus, Obwalden, Ticino and Uri, there were no official vaccinations in pharmacies in either season. * Comparison between pharmacies 2016/17 and
2017/18.
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Benefits and costs of influenza vaccinations adminis-
tered in pharmacies
The economic and public health benefits generated by vac-
cination in pharmacies and the associated costs and bene-
fits are listed in table 5. For each vaccination, there was a
net return of CHF 13.40 into the economy. For the 2017/
18 influenza season, the total net return in Switzerland
amounted to more than CHF 143,000. Table 6 depicts the
costs and benefits of influenza vaccination in pharmacies
in individual cantons per 100,000 population in the 2017/
18 influenza season. Cantons not listed did not carry out
prescriptionless influenza vaccinations in pharmacies. For
all of Switzerland and per 100,000 inhabitants, a net prof-
it of CHF 1918 was calculated, and 94.4 cases of illness,
17.6 visits to primary care physicians, 0.328 hospitalisa-
tions, 1.1 hospitalisation days and 0.019 deaths were pre-
vented, and 0.353 life-years gained. However, large differ-
ences were found between cantons. The highest net savings
per 100,000 population for 2017/18 were detected in the
canton of Basel-Landschaft (CHF 13,318 per 100,000 pop-
ulation), whereas in the canton of Schaffhausen only CHF
437 per 100,000 population was saved.
Benefits and costs of influenza vaccination as a func-
tion of vaccination coverage in the working-age popu-
lation
As outlined in the Methods section, net savings are expect-
ed as soon as the marginal effectiveness of the influenza
vaccine is exceeded. This depends directly on the costs of
the vaccination and inversely on the costs of a case of ill-
ness and the attack rate, and is in the range of 38% with the
assumptions made by Piercy and Miles. Due to the dispro-
portionate increase in the costs of vaccination in relation to
the costs incurred by influenza illness (see table 1), mar-
ginal effectiveness rose to 59%.
Table 4: Vaccinations in pharmacies authorised to vaccinate in the 2016/17 and 2017/18 influenza seasons.
Both seasons 2016/17 influenza sea-
son
2017/18 influenza season p-value*
All of Switzerland
Number of vaccinations administered 22,923 7306 (0.09) 15,617 (0.18) <0.001
Vaccinated population Age, years, mean (SD) 55.7 (16.0) 55.4 (16.2) 55.8 (16.0) 0.24
Female sex, n (%) 12,049 (52.6) 3910 (53.5) 8139 (52.1) 0.049
Age groups 0‒18 years, n (%) 264 (1.2) 100 (1.4) 164 (1.1)
19‒65 years, n (%) 15,625 (68.2) 4966 (68.0) 10,659 (68.3) 0.11
>65 years, n (%) 7034 (30.7) 2240 (30.7) 4794 (30.7)
Number of vaccinationss by canton
Bern 3821 1261 (0.12) 2560 (0.25) <0.001
Basel-Landschaft 3686 1360 (0.48) 2326 (0.81) <0.001
Fribourg 1057 480 (0.15) 577 (0.18) 0.005
Geneva 935 339 (0.07) 596 (0.12) <0.001
Graubünden 888 295 (0.15) 593 (0.30) <0.001
Jura 244 110 (0.15) 134 (0.18) 0.14
Lucerne 421 421 (0.10) n.a.
Neuchâtel 458 114 (0.06) 344 (0.19) <0.001
Nidwalden/Schwyz† 524 60 (0.03) 464 (0.23) <0.001
Saint Gallen 1065 340 (0.07) 725 (0.14) <0.001
Schaffhausen 41 19 (0.02) 22 (0.03) 0.76
Solothurn 1280 467 (0.17) 813 (0.30) <0.001
Thurgau 573 221 (0.08) 352 (0.13) <0.001
Vaud 1191 345 (0.04) 846 (0.11) <0.001
Valais 691 212 (0.06) 479 (0.14) <0.001
Zug 475 475 (0.38) n.a.
Zurich 5573 1683 (0.11) 3890 (0.26) <0.001
n.a. = not applicable Figures in brackets correspond, unless otherwise indicated, to the percentage of the total population. In the cantons of Aargau, Appenzell Innerrhoden,
Appenzell Ausserrhoden, Basel-Stadt, Glarus, Obwalden, Ticino and Uri, there were no official vaccinations in pharmacies in either season * Comparison between 2016/17 and
2017/18 influenza seasons. † For reasons of data protection, only combined figures were provided for these two cantons.
Table 5: Costs and benefits of influenza vaccination in pharmacies in the 2016/17 and 2017/18 seasons for the 19‒65 age group.
2016/17 influenza season 2017/18 influenza season
Number vaccinated 4966 10,659
Public health benefits Influenza cases prevented 392 842
Visits to primary care physicians prevented 73 157
Hospitalisations prevented 1.36 2.93
Hospitalisation days prevented 4.50 9.65
Deaths prevented 0.08 0.17
Number of life-years saved 1.47 3.15
Economic impact Costs of vaccination, CHF 190,496 408,879
Benefits from vaccination, CHF 257,129 551,901
Net benefits, CHF 66,633 143,021
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Figure 1 shows the net benefit of influenza vaccination in
the 19‒65 years age group as a function of vaccine cov-
erage. At a low vaccine coverage of only 10%, a margin-
ally effective vaccine with an efficacy of 10% results in a
loss of CHF 15.6 million, whereas an efficacy of 40% re-
sults in a loss of CHF 6.0 million and an efficacy of 80%
in a CHF 6.9 million net benefit. If the vaccination cover-
age rate were 50%, the corresponding costs would be CHF
77.9 million for 10% efficacy and CHF 29.8 million for
40% efficacy, and the benefit for 80% efficacy could reach
CHF 34.4 million. A vaccination coverage rate of 100%
would result in losses of CHF 155.9 million for 10% effi-
cacy and CHF 59.5 million for 40% efficacy, or lead to a
net benefit of CHF 69.0 million at 80% efficacy.
Discussion
Pharmacies in Switzerland have been offering prescrip-
tion-free influenza vaccination for healthy adults since the
2015/16 influenza season. Influenza vaccinations in phar-
macies could contribute to an increase in the vaccination
Table 6: Costs and benefits of influenza vaccination for healthy 19- to 65-year-olds in the pharmacies of the individual cantons per 100,000 population in the 2017/18 influenza
season. The denominator corresponds to healthy 19- to 65-year-olds on 31 December 2017.
Canton Costs of vaccina-
tion
(CHF)
Benefits from
vaccination
(CHF)
Net bene-
fits
(CHF)
Influenza
cases pre-
vented
Visits to pri-
mary care
physicians
prevented
Hospitalisations
prevented
Hospitalisation
days prevent-
ed
Deaths pre-
vented
Number of
life-years
saved
Bern 11,432 15,431 3999 25.6 4.8 0.089 0.6 0.005 0.096
Basel-Landschaft 38,074 51,391 13,318 72.2 13.5 0.251 2.1 0.015 0.270
Fribourg 8285 11,183 2898 16.6 3.1 0.058 0.6 0.003 0.062
Geneva 5444 7349 1904 13.2 2.5 0.046 0.5 0.003 0.049
Graubünden 13,600 18,357 4757 23.6 4.4 0.082 1.1 0.005 0.089
Jura 8669 11,702 3032 17.6 3.3 0.061 0.9 0.004 0.066
Lucerne 4653 6281 1628 9.0 1.7 0.031 0.5 0.002 0.034
Neuchâtel 8914 12,032 3118 18.2 3.4 0.063 1.0 0.004 0.068
Nidwalden/Schwyz* 10,345 13,964 3619 19.2 3.6 0.067 1.2 0.004 0.072
Saint Gallen 6513 8791 2278 13.6 2.5 0.047 0.9 0.003 0.051
Schaffhausen 1250 1687 437 2.6 0.5 0.009 0.2 0.001 0.010
Solothurn 13,587 18,339 4753 26.3 4.9 0.092 1.9 0.005 0.099
Thurgau 5779 7800 2,021 11.3 2.1 0.039 0.9 0.002 0.042
Vaud 4862 6562 1701 10.0 1.9 0.035 0.9 0.002 0.037
Valais 6425 8672 2247 14.8 2.8 0.052 1.4 0.003 0.056
Zug 16,903 22,815 5912 39.8 7.4 0.138 3.8 0.008 0.149
Zurich 11,520 15,550 4030 23.1 4.3 0.080 2.3 0.005 0.087
Switzerland 8343 11,262 2918 94.4 17.6 0.328 1.1 0.019 0.353
* For reasons of data protection, only combined figures were provided for these two cantons.
Figure 1: Expected net economic benefit from influenza vaccination in the group of healthy adults aged 19‒65 years in relation to vaccine ef-
fectiveness. The different colours indicate vaccination coverage rates in the population.
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rate in the population as a whole by facilitating access
to vaccination, and be of particular interest if vaccination
recommendations were extended to a broader population,
such as in the context of influenza pandemics.
In a comprehensive analysis of available data, we demon-
strated that so far only a very small proportion of influenza
vaccinations (1.4% of all vaccine doses delivered in
Switzerland in the 2017/18 season) were administered in
pharmacies at the customer’s expense. Although this pro-
portion doubled between the 2016/17 and 2017/18 seasons,
it is still negligible in comparison with the main target
group of potential customers, consisting of around 5.4 mil-
lion people between 19 and 65 years of age, of whom
around 91% – that is to say, 4.9 million people – do not
belong to any risk group and therefore do not qualify for
reimbursement of influenza vaccine costs by their health
insurance provider. In the 2017/18 season, only 0.18% of
the Swiss population were vaccinated in pharmacies. From
the 2016/17 to the 2017/18 season, the proportion of vac-
cinating pharmacies increased to 24.5% of all pharmacies
in the cantons that fulfil the legal requirements. The dou-
bling of the number of vaccinations administered in phar-
macies between the two periods is disproportionately high
compared with the increase in the overall supply of vac-
cine doses in the same period. Furthermore, the proportion
of vaccines administered in settings that qualify for cov-
erage by health insurance providers decreased in the same
period to 4.5% of the Swiss population. However, because
of the small number of people vaccinated in pharmacies,
it is not possible to determine whether the availability of
this service had an influence on vaccinations in other set-
tings or on the overall vaccination rate. It remains to be
seen whether this new service complements or competes
with traditional ways to get vaccinated.
We also found that the net cost saving for the Swiss econ-
omy due to the vaccinations administered in pharmacies
was CHF 66,633 in the 2016/17 and CHF 143,021 in the
2017/18 influenza season. For 2017/18 and per 100,000
population, we calculated a net profit of CHF 1918 and
demonstrated that 94.4 cases of illness, 17.6 visits to pri-
mary care physicians, 0.328 hospitalisations, 1.1 hospital-
isation days and 0.019 deaths were prevented, and 0.353
life-years gained. Put in context, these cost savings seem
negligible compared with the CHF 80.5 billion of health-
care expenses in Switzerland in 2016 [26]. Projections for
the working population show, however, that with a vac-
cination coverage rate of 50% and a vaccine efficacy of
70%, the Swiss economy could save almost CHF 20 mil-
lion annually. This number could even be increased to CHF
66 million if the cost per influenza vaccine could be re-
duced from CHF 38.35 (as used for the current analysis)
to the 1999 level of around CHF 20.65, which seems fea-
sible in view of the factory sale prices of just under CHF
10. Based on considerations with regard to marginal effec-
tiveness, however, a vaccine effectiveness of around 60%
is needed to reach breakeven. This level of effectiveness
is usually reached in the population of 19- to 65-year-olds,
although is not guaranteed [11–14].
Our study has several weaknesses. Any quantitative analy-
sis depends on the underlying original data, and the data
sources we used have limitations. The vaccination data for
the vaccine doses supplied to Switzerland included only
the doses delivered, but not the doses actually adminis-
tered. According to Swiss FOPH estimates, 5‒10% of all
doses sold are not administered. The data from the phar-
macies is limited to pharmacies participating in phS-net.ch,
which entered vaccination data into the system on a vol-
untary basis. This results in an underestimation of the vac-
cinations administered in pharmacies, compounded by the
fact that pharmacies not participating in phS-net.ch also of-
fered vaccinations. Analyses recently published by phar-
maSuisse attempt to address this underestimation by means
of extrapolation, which is also subject to a significant de-
gree of uncertainty [18]. The extrapolation by pharmaSu-
isse includes 19,648 vaccinations in the 2017/18 season,
whereas the data set made available to us contained 15,617
vaccinations registered in phS-net.ch. The figures calcu-
lated in the current study therefore represent a conserva-
tive view of the vaccinations administered in pharmacies.
The study by pharmaSuisse supports our finding that on-
ly a small proportion of vaccinations were administered in
pharmacies, compared with physicians’ offices, especially
in the age group over 65, and did not find any evidence of
a shift in influenza vaccinations from primary care physi-
cians to pharmacies either.
Our assumptions regarding the economic benefits and dis-
advantages of influenza vaccination and the methododol-
ogy used were based on the publication by Piercy and
Miles [4]. Although the assumptions in that publication
were based on a literature search, original data, and inter-
views with national and international experts, the decision
analysis uses a modelling approach that cannot be com-
pared with empirical data collection and analysis. Some
of the assumptions of Piercy and Miles were adopted for
the present analysis owing to a lack of current literature
and some were enriched with current data. Even though
such factors were not obvious to us, we cannot exclude
the possibility that other effects, due to changing parame-
ters that affect influenza epidemiology, may have biased
our methodological approach, which dated back to 1999.
Piercy and Miles did not carry out a cost-benefit analysis
in their study, the authors claiming that such a study re-
quired a financial evaluation of prevented deaths and years
of life gained, for which they could not identify a suitable
method. Although they pointed to the social benefits of
influenza vaccination for healthy, working adults in their
summary section, they do not elaborate on these results in
the main text. In contrast, they calculated the cost of in-
fluenza vaccination per death prevented or per quality-ad-
justed year of life gained in the risk groups studied. This
approach, however, is also not above criticism as it gives
society a choice regarding how much it wants to invest in
preventing a death in the corresponding population. At the
same time, it does not take into account the social benefits
of preventing illnesses not resulting in death or a loss of
life-years. The data presented by Piercy and Miles suggest
that vaccinating healthy adults at a cost of CHF 1.2 million
per death prevented is not cost-effective, which has been
used as an argument for not recommending vaccination for
this population. Our data clearly show that the vaccination
of this population can have an economic benefit and should
therefore be taken into consideration in the evaluation of
vaccine recommendations, even if the number of deaths
prevented is low. A further weakness of our study lies in
its lack of generalisability and applicability to other health-
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care systems. At the same time, the strong, individualised
focus on the Swiss setting and the Swiss healthcare system
can be interpreted as a great strength.
In conclusion, influenza vaccination for healthy 19-
65-year-olds results in an economic benefit as long as the
marginal effectiveness of the influenza vaccine exceeds a
threshold of approximately 60%. For this reason, vaccina-
tion in this age category is supported from both an eco-
nomic and a health policy point of view. It may thus be in-
dicated to assess whether a change of the recommendations
for this age group is advisable in Switzerland, similar to
other countries that even recommend universal vaccination
of all age groups [27–29]. Pharmacies may be useful in
implementing an expansion of vaccination recommenda-
tions, addressing the increase in demand. A decisive ques-
tion regarding the expansion of vaccination recommenda-
tions, howewer, is the question of costs. At the moment,
those individuals who pay for vaccination bear both the
costs and adverse effects, and thereby support society as a
whole, from a financial and a public health perspective, es-
pecially if herd immunity is also taken into consideration
[30–32]. One explanation for low vaccination rates might
be that only few people currently weigh the personal bene-
fit associated with influenza vaccination as higher than the
costs associated with vaccination. In other words, self-in-
terest is more prevalent in the population than the utilitar-
ian view, which takes into account the overall benefits for
society [33]. Protection against influenza infection can be
considered a public good in the utilitarian sense. The ques-
tion then arises as to whether, as for other public goods,
there is a need to influence vaccination coverage by means
of incentives for those vaccinated (e.g., absorption of the
costs of vaccination and/or reduction of health insurance
premiums) or of disadvantages for unvaccinated persons
(e.g., increase in health insurance premiums and/or a lack
of compensation for losses due to illness) in order to better
protect population health.
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Appendix 1 Supplementary tables
Table S1: List of influenza vaccines, retrieved from the Sasis datapool.
Name of vaccine Ex-factory price
(CHF)
Active substance Manufacturer
Mutagrip, Inj Susp 2016/2017, Fertspr 0.500 ml 8.51 Vaccinum influenzae-Split, inactivatum 2016/2017 Sanofi-Aventis (Suisse) SA
Mutagrip, Inj Susp 2017/2018, Fertspr 0.500 ml 8.51 Vaccinum influenzae-Split, inactivatum 2017/2018 Sanofi-Aventis (Suisse) SA
Influvac, Inj Susp 2016/2017, Fertspr 0.500 ml 9.10 Vaccinum influenzae-Subunit inactivatum 2016/2017 BGP Products GmbH
Influvac, Inj Susp 2017/2018, Fertspr 0.500 ml 9.10 Vaccinum influenzae-Subunit inactivatum 2017/2018 BGP Products GmbH
Fluad, Inj Susp 2016/2017, Fertspr 0.500 ml 10.05 Vaccinum influenzae-Subunit inactivatum, adjuvantum
2016/2017
PaxVax Berna GmbH
Fluad, Inj Susp 2017/2018, Fertspr 0.500 ml 10.05 Vaccinum influenzae-Subunit inactivatum, adjuvantum
2017/2018
PaxVax Berna GmbH
Agrippal, Inj Susp 2016/2017, Fertspr 0.500 ml 9.10 Vaccinum influenzae-Subunit inactivatum 2016/2017 PaxVax Berna GmbH
Agrippal, Inj Susp 2017/2018, Fertspr 0.500 ml 9.10 Vaccinum influenzae-Subunit inactivatum 2017/2018 PaxVax Berna GmbH
Fluarix Tetra, Inj Susp m sep Nad 2016/2017, 0.500 ml 9.27 Vaccinum influenzae-Split, inactivatum, tetravalens
2016/2017
GlaxoSmithKline AG
Fluarix Tetra, Inj Susp m sep Nad 2017/2018, 0.500 ml 9.27 Vaccinum influenzae-Split, inactivatum, tetravalens
2017/2018
GlaxoSmithKline AG
Table S2: Assumptions, from the publication by Piercy and Miles [4], that were used for the analyses.
Variable Value
Age range 15‒65 years
Population size 4,235,000
Employment rate 78%
Proportion of subjects from high-risk populations 9.04%
Vaccination rate 9.54%
Attack rate 10%
Duration of influenza season 10 weeks
Sick days due to influenza 8.3
Lost working days (without need for physician visit) per illness episode 4.5
Lost working days (with need for physician visit) per illness episode 5.5
Lost working days due to reduced efficiency after return, per illness episode 0.35
Lost working hours due to vaccination at the workplace, per vaccinated person 0.5
Percentage of vaccinated persons with primary physician visit due to adverse effects of vaccination 0.5%
Lost working days due to primary physician visit due to adverse effects of vaccination, per vaccination 0.01
Direct costs of illness, Switzerland, CHF 41,684,816
Indirect costs of illness, Switzerland, CHF 168,834,228
Totale costs of illness, Switzerland, CHF 210,519,044
Working days lost due to illness, Switzerland 1,058,373
Costs caused by vaccination, Switzerland, CHF 8,341,600
Vaccine effectiveness (prevention of disease) 79%
Number of influenza cases, Switzerland 391,569
Number of influenza cases prevented by vaccination, Switzerland 31,931
Vaccine effectiveness (prevention of primary physician visits) 32%
Visits to primary care physicians per year due to influenza, Switzerland 190,524
Number of visits to primary care physicians prevented by vaccination, Switzerland 5964
Vaccine effectiveness (prevention of hospitalisations) 46%
Hospitalisations due to influenza, per year, Switzerland 2,421
Number of hospitalisations prevented by vaccination, Switzerland 111
Hospital days per year, Switzerland 7986
Number of hospital days prevented by vaccination, Switzerland 365
Vaccine effectiveness (prevention of death) 65%
Mortality per 10,000 population 0.025
Deaths per year, Switzerland 99
Number of deaths prevented by vaccination, Switzerland 7
Life-years lost due to influenza per year, Switzerland 1808
Loss of life-years prevented by vaccination, Switzerland 120
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